Business
CelLBxHealth PLC Announces Preliminary Fourth Quarter 2025 Financial Results
GUILDFORD, SURREY / ACCESS Newswire / January 16, 2026 / CelLBxHealth plc (AIM:CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, announces an update ...
About this update from Cellbxhealth Plc
[{"type":"text","content":"GUILDFORD, SURREY / ACCESS Newswire / January 16, 2026 / CelLBxHealth plc (AIM:CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, announces an update on 2025 unaudited financial results and further cost rationalisation as it looks to drive commercial progress in 2026.","length":365,"tagName":"p"},{"type":"text","content":"Preliminary 2025 financial results","length":34,"tagName":"p"},{"type":"text","content":"The Company now expects to report fourth quarter and full year 2025 revenues of approximately £0.4 million and £1.4 million respectively. The full year biopharma and product revenues were £0.3 million and £1.1 million respectively. The Company was expecting to achieve revenues of £1.6million for the year ended 31 December 2025, however a few sales contracts, with an aggregate value of approximately £0.2 million, were deferred into the first quarter of 2026.","length":461,"tagName":"p"},{"type":"text","content":"Cash at 31 December 2025 was £7.3 million, providing a strong balance sheet from which to execute on the new strategy.","length":118,"tagName":"p"},{"type":"text","content":"Cost rationalisation","length":20,"tagName":"p"},{"type":"text","content":"The Company is reducing costs at all levels and consequently has voluntarily delisted its ordinary shares from trading on the OTCQX Market due to low trading volume and the associated administrative requirements. The Company's last day of trading on the OTCQX Market was 31 December 2025. Beginning 2 January 2026, the Company has transitioned to trading on the Pink Limited Market.","length":386,"tagName":"p"},{"type":"text","content":"The Company is also rationalising its operations at Guildford into one facility. Along with headcount reductions and other restructuring activities, total cost savings are expected to be approximately £5.9 million on an annualised basis.","length":237,"tagName":"p"},{"type":"text","content":"Outlook for 2026","length":16,"tagName":"p"},{"type":"text","content":"Further to the fundraising announced in late November 2025, the Company is now pursuing its revised business strategy, focused on the delivery of commercial milestones from its qualified 2026/27 sales pipeline of approximately £12.6 million (risk weighted pipeline of £4.5 million), which...